<PAGE>
FORM 8-K
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 15, 1999
ROBERTS PHARMACEUTICAL CORPORATION
- --------------------------------------------------------------------------------
(exact name of registrant as specified in its charter)
New Jersey 1-1-432 22-2429994
- ------------------------- ---------------- --------------------
(State or other (Commission (IRS Employer
jurisdiction of File Number Identification
incorporation Number
Meridian Center II
4 Industrial Way West
Eatontown, New Jersey 07724
- --------------------------------------------------------------------------------
(Address of principal executive offices, including zip code)
Registrant's telephone number, including area code: 732-676-1200
- --------------------------------------------------------------------------------
(Former name or former address, if changed from last report)
<PAGE>
- 2 -
Item 5. Other Events
------------
Roberts Pharmaceutical Corporation yesterday afternoon presented
at the 17th annual Hambrecht & Quist Healthcare Conference in San Francisco.
The Company's presentation at this meeting of investment managers reflected
Roberts' optimism over its long-term growth prospects.
Based on currently available information, Roberts expects strong
incremental annual growth over the next few years to be supported by anticipated
increased market penetration of its new high-margin products Agrylin(R),
ProAmatine(R), and Pentasa(R).
Revenue growth should be further enhanced by potential acquisitions of
in-market products and future product flow from the development pipeline. With
regard to the former, the company actively pursues opportunities to acquire
high-potential, but under-promoted drugs that can add to both its top and bottom
lines, enhance cash flow, complement its pipeline programs, and are consistent
with its marketing strengths.
Roberts believes that annual growth in profitability over the coming
years should be driven by a combination of factors including anticipated growth
in revenues, further strengthening in gross profit margins, and additional
reductions in sales, general, and administration (SG&A) expenses as a percentage
of revenues.
The Company's product pipeline includes several compounds in late-stage
development that collectively represent potential future U.S. sales estimated at
over $1.5 billion. Many of these products also represent worldwide
opportunities for Roberts.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ROBERTS PHARMACEUTICAL CORPORATION
----------------------------------
(Registrant)
Date: January 19, 1999 By: /s/ Anthony A. Rascio
-----------------------------
Anthony A. Rascio
Vice President
<PAGE>
- 3 -
FORWARD LOOKING STATEMENTS
Certain statements included in Item 5 of this form 8-K are intended to
be, and are hereby identified as, forward looking statements for purposes of the
safe harbor provided by Section 21E of the Securities Exchange Act of 1934, as
amended, and Section 27A of the Securities Act of 1933, as amended. The
Registrant cautions readers that forward looking statements, including, without
limitation, those relating to the Registrant's future business prospects,
revenues, cost of sales, intangible dispositions and write-offs, continuing
operations and discontinued operations, and liquidity and capital resources, are
subject to certain risks and uncertainties, including, without limitation, the
ability of the Registrant to secure regulatory approval in the United States and
in foreign jurisdictions for the Registrant's developmental pipeline drugs, the
efforts of the Registrant's competitors and the introduction of rival
pharmaceutical products which may prove to be more effective than the
Registrant's products, general market conditions, the availability of capital,
and the uncertainty over the future direction of the healthcare industry, that
could cause actual results to differ materially from those indicated in the
forward looking statements.
